Sponsored by
Your agents work while you sleep
Give a Skydive agent an ongoing responsibility and they’ll handle it on schedule, every time.
Have them prep your morning report, research new leads, monitor customer feedback, or keep projects moving overnight. You wake up, the work is already done.
Pharmaceutical research has always faced one expensive problem. Most drug candidates fail before reaching patients. A 2024 Nature analysis noted that only about 10 percent of clinical drug programs eventually receive approval. This failure rate drives much of the industry’s development cost.
AI is beginning to change where those failures happen and how quickly researchers identify them.
Finding better drug candidates earlier
Traditional discovery requires researchers to screen compounds, study biological targets, and repeatedly test possible molecules. AI can process molecular, genetic, protein, and disease data at far greater scale.
Newer models can predict protein interactions, rank possible drug targets, generate molecular structures, and estimate how compounds may behave before laboratory testing begins.
This is no longer limited to computer simulations. In 2025, Nature Medicine reported results from a randomized phase 2a trial involving an AI-discovered drug and target combination for idiopathic pulmonary fibrosis. Researchers reported safety and signs of efficacy, marking an important clinical milestone for AI-assisted drug discovery.
Hiring in a new country? Read this first.
Every country has different employment laws, payroll requirements, notice periods, and benefits expectations.
Oyster's Global Hiring Guides help you navigate the details, avoid surprises, and hire with confidence—wherever you're growing next.
Changing how clinical trials are designed
AI may have an equally large effect after discovery.
Clinical trials require patient recruitment, protocol design, data monitoring, safety analysis, and regulatory documentation. AI systems are increasingly being tested across each of these areas.
Nature Biotechnology reported in 2025 that AI tools are being used to support patient selection, protocol development, interim data analysis, and trial reporting. The journal also noted early evidence that some AI-discovered drugs have performed strongly in phase 1 studies, although larger datasets are still needed before drawing broad conclusions.
The main value may therefore come from better decisions. Companies could stop weak programs earlier and direct capital toward stronger candidates.
Regulators are preparing for AI-based evidence
Regulatory agencies are no longer treating pharmaceutical AI as an experimental side issue.
The US FDA says its Center for Drug Evaluation and Research reviewed more than 500 submissions containing AI components between 2016 and 2023. These applications covered nonclinical research, clinical development, manufacturing, and post-market activities.
In January 2026, the FDA and European Medicines Agency jointly published ten principles for good AI practice in drug development. They emphasize human oversight, risk-based evaluation, data governance, documentation, model performance, and lifecycle management.
The EMA has also established guidance covering AI use from drug discovery through post-authorisation monitoring.
Manufacturing and safety may change too
The pharmaceutical impact extends beyond discovering new medicines.
AI can help identify manufacturing deviations, analyze production data, forecast quality risks, and support process control. After a medicine reaches the market, machine learning can also assist pharmacovigilance teams by processing adverse-event reports and identifying possible safety signals.
These applications receive less public attention than AI-generated molecules. Yet they may produce substantial operational gains because they affect medicines already serving large patient populations.
The research still carries limits
AI does not remove biological uncertainty.
A model can predict a promising molecule and still fail to predict what happens inside a human body. Training data may contain bias. Models may perform poorly outside their original datasets. Some systems are difficult to explain or reproduce.
A 2026 Nature Reviews Drug Discovery assessment reflects this more measured stage of the field. AI is becoming part of real pharmaceutical research, but its long-term effect will depend on scientific validation and clinical evidence rather than computational performance alone.
The pharmaceutical industry is therefore moving toward a different research model. Human scientists still make the medical decisions. AI increasingly determines which possibilities deserve their attention first.
That shift may prove more important than simply discovering drugs faster. It changes how pharmaceutical companies decide what is worth pursuing at all.
Build. Break. Fix. Learn.
KodeKloud gives you 1,280+ hands-on labs where you provision Kubernetes clusters, write Terraform configs, build CI/CD pipelines, configure Linux systems, containerize apps with Docker, automate with Ansible, and manage Git workflows.
78+ playgrounds let you experiment freely in sandbox AWS environments, Kubernetes clusters, and CI/CD systems without risk.
190+ courses across DevOps, Cloud, and AI pair theory with hands-on labs at every step.
KodeKloud Engineer and 100 Day Challenges provide real-world job scenarios with automated grading that confirms your solutions work.
Stuck? The 55,000+ member Discord community connects you with peers and instructors ready to help.
Every lab runs in a live environment. You deploy, you troubleshoot, you learn. No videos without context. No simulations. The kind of practice that actually builds confidence because you've done real work, not watched someone else do it.
